“기흥오피🐏 （OPDAL020.컴）오피달리기 🍠기흥건마🍌기흥스파🌧기흥마사지🗿기흥마사지🈚️기흥마사지🙅기흥스파👑”的搜索结果，显示 251-260 项，共有 15861 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with advanced gastric and GEJ adenocarcinoma. Accelerated Vs ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with advanced gastric and GEJ adenocarcinoma. Pre-myeloid ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Rochester, Minn. Levels of bladder cancer-derived extracellular vesicles become undetectable after radical cystectomy in patients with localized bladder cancer.

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The purpose of this study is to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with Cemiplimab.

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The primary objective of this study is to determine the confirmed investigator-assessed objective response rate of XMT-1536 (upifitamab rilsodotin) in ...

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with advanced gastric and GEJ adenocarcinoma. Assessing the ...

8. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The primary objective of this study is to determine the confirmed investigator-assessed objective response rate of XMT-1536 (upifitamab rilsodotin) in ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with advanced gastric and GEJ adenocarcinoma. Pre-myeloid ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    The primary objectives for this study are: The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of ...